Science Explorer Back to mapMap
Discussion
Institution · Eli Lilly (United Kingdom)

Most cited papers from Eli Lilly (United Kingdom)

Eli Lilly (United Kingdom)

What are the most cited papers from Eli Lilly (United Kingdom)?

The most cited paper from Eli Lilly (United Kingdom) is "Biological insights from 108 schizophrenia-associated genetic loci" (Stephan Ripke et al., 2014), with 8,181 citations. Next come "Mapping genomic loci implicates genes and synaptic biology in schizophrenia" (2,894) and "International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors" (2,839).

Showing 50 of 60 papers. Every paper with more than 237 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Biological insights from 108 schizophrenia-associated genetic loci Stephan Ripke et al. · Nature Open access297 authors Jul 2014 8,181
2 Mapping genomic loci implicates genes and synaptic biology in schizophrenia Vassily Vladimirovich Trubetskoy et al. · Nature Open access613 authors 8 Apr 2022 2,894
3 International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors A­llyn C. Howlett, F. Barth, T.I. Bonner et al. · Pharmacological Reviews Jun 2002 2,839
4 Definition and diagnostic criteria of clinical obesity Francesco Rubino et al. · The Lancet Diabetes & Endocrinology Open access 14 Jan 2025 1,660
5 Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects Christian R. Marshall et al. · Nature Genetics Open access263 authors 21 Nov 2016 1,160
6 Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine Frank P. Bymaster, David O. Calligaro, Julie F. Falcone et al. · Neuropsychopharmacology Open access Feb 1996 1,075
7 Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1 Jeroen Paul Jansen, Rachael Fleurence, Beth Devine et al. · Value in Health Open access Jun 2011 1,053
8 Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2 David C. Hoaglin, Neil Hawkins, Jeroen Paul Jansen et al. · Value in Health Open access Jun 2011 774
9 The prevalence of urinary incontinence in women in four European countries Steinar Hunskaar, Gunnar Lose, David Sykes et al. · British Journal of Urology Feb 2004 765
10 Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel John T. Brandt, Sandra L. Close, Stephen J. Iturria et al. · Journal of Thrombosis and Haemostasis Open access 27 Sep 2007 735
11 MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer Stephen R.D. Johnston, Miguel Martín, Angelo Di Leo et al. · npj Breast Cancer Open access 11 Jan 2019 693
12 Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model Ian F. Harrison, Ozama Ismail, Asif Machhada et al. · Brain Open access 14 May 2020 671
13 The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia Josep María Haro, Shanta Kamath, Susana Ochoa et al. · Acta Psychiatrica Scandinavica May 2003 665
14 Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial William D. Tap, Robin L. Jones, Brian Andrew Van Tine et al. · The Lancet Open access 12 Jun 2016 595
15 Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs Open access 11 Jun 2014 576
16 On the path to 2025: understanding the Alzheimer’s disease continuum Paul S. S. Aisen, Jeffrey L. Cummings, Clifford R. Jack et al. · Alzheimer s Research & Therapy Open access 9 Aug 2017 575
17 Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway Michael M. F. Lahn, Stephan Herbertz, J. Scott Sawyer et al. · Drug Design Development and Therapy Open access Aug 2015 552
18 Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders Swedish Schizophrenia Study et al. · Nature Neuroscience Open access 14 Mar 2016 484
19 A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity Zeshan Ahmed, Jane Cooper, Tracey K. Murray et al. · Acta Neuropathologica Open access 16 Feb 2014 481
20 Epidemiology of diabetic retinopathy and macular oedema: a systematic review Rhys Williams, M. Airey, Hazel Baxter et al. · Eye Review 2 Jul 2004 476
21 Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues Viktor Lakics, Eric H. Karran, Frank Boess · Neuropharmacology 22 May 2010 471
22 Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia Diego Novick, Josep María Haro, David L. Suarez et al. · Psychiatry Research 25 Feb 2010 454
23 Synaptic Connections and Small Circuits Involving Excitatory and Inhibitory Neurons in Layers 2-5 of Adult Rat and Cat Neocortex: Triple Intracellular Recordings and Biocytin Labelling In Vitro Alex M. Thomson · Cerebral Cortex Sep 2002 438
24 A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission Vernon R. J. Clarke, Barbara A. Ballyk, Ken H. Hoo et al. · Nature Oct 1997 416
25 Developing attributes for a generic quality of life measure for older people: Preferences or capabilities? Ini Grewal, Jane E. A. Lewis, Terry Nicholas Flynn et al. · Social Science & Medicine 16 Sep 2005 411
26 Health state utilities for non small cell lung cancer Beenish Nafees, Megan Rose Stafford, Sonia Gavriel et al. · Health and Quality of Life Outcomes Open access 2008 405
27 Protection of Cattle Against Foot-and-Mouth Disease by a Synthetic Peptide Richard D. DiMarchi, Gerald S. Brooke, CHARLES C. GALE et al. · Science 2 May 1986 401
28 An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation Eilis J. Hannon et al. · Genome biology Open access 23 Aug 2016 393
29 Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer D. A. Fennell, Yvonne Jane Summers, J. Cadranel et al. · Cancer Treatment Reviews 4 Feb 2016 388
30 IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis James G. Krueger, Scott Fretzin, Mayte Suárez‐Fariñas et al. · Journal of Allergy and Clinical Immunology Open access 5 Jun 2012 388
31 CSF biomarker variability in the Alzheimer's Association quality control program Niklas Mattsson et al. · Alzheimer s & Dementia Open access145 authors May 2013 386
32 A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates Masoud Jamei, Gemma L. Dickinson, Amin Rostami‐Hodjegan · Drug Metabolism and Pharmacokinetics 2009 370
33 Health state utilities for metastatic breast cancer Andrew J. Lloyd, Beenish Nafees, J Narewska et al. · British Journal of Cancer Open access Sep 2006 368
34 Ultrastructural Distribution of the α7 Nicotinic Acetylcholine Receptor Subunit in Rat Hippocampus Ruth Fabian‐Fine, Paul Skehel, Mick L. Errington et al. · Journal of Neuroscience Open access 15 Oct 2001 364
35 Crystal structures of the M1 and M4 muscarinic acetylcholine receptors David M. Thal, Bingfa Sun, Dan Feng et al. · Nature Open access 8 Mar 2016 359
36 Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models Xiyun Chai, Su Wu, Tracey K. Murray et al. · Journal of Biological Chemistry Open access 13 Aug 2011 358
37 Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials Mary Bouxsein, Richard Eastell, Li‐Yung Lui et al. · Journal of Bone and Mineral Research Open access 23 Jan 2019 354
38 Meta-Analysis of the Alzheimer’s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models Ying‐Wooi Wan et al. · Cell Reports ReviewOpen access Jul 2020 341
39 A genome-wide association study of anorexia nervosa V Boraska et al. · Molecular Psychiatry Open access218 authors 11 Feb 2014 336
40 Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models Athina N. Markou, Cristiano Chiamulera, Mark A. Geyer et al. · Neuropsychopharmacology Open access Oct 2008 327
41 Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial Hartmut Porst, Harin Padma-Nathan, François Giuliano et al. · Urology 30 Jun 2003 327
42 Sparing of the familiarity component of recognition memory in a patient with hippocampal pathology John P. Aggleton, Seralynne D. Vann, Christine E. Denby et al. · Neuropsychologia 2005 323
43 Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel David S. Small, Nagy A. Farid, Christopher D. Payne et al. · The Journal of Clinical Pharmacology 27 Feb 2008 316
44 Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas William D. Tap et al. · JAMA Open access 7 Apr 2020 312
45 Health state utilities in non–small cell lung cancer: An international study Beenish Nafees, Andrew J. Lloyd, Sarah Dewilde et al. · Asia-Pacific Journal of Clinical Oncology 17 Mar 2016 312
46 Double-Blind, Placebo-Controlled Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in the Treatment of Acute Agitation in Schizophrenia Pádraig Wright, Martin A. Birkett, Stacy R. David et al. · American Journal of Psychiatry Jul 2001 303
47 Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial Wim M. Mulleners, Byung‐Kun Kim, Miguel J. A. Láinez et al. · The Lancet Neurology 16 Sep 2020 293
48 Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer Davide Melisi, Rocio García‐Carbonero, Teresa Mercade Macarulla et al. · British Journal of Cancer Open access 10 Oct 2018 289
49 The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. Nicholas Moore, Nicholas C. Tye, Mich�leS. Axton et al. · Journal of Pharmacology and Experimental Therapeutics Aug 1992 278
50 Conformation Determines the Seeding Potencies of Native and Recombinant Tau Aggregates Benjamin Falcon, Annalisa Cavallini, Rachel C. Angers et al. · Journal of Biological Chemistry Open access 19 Nov 2014 272

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.